PATENT CLAIM ANALYSIS

Application Number: 15991326
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.

Claim (Index 21):
The oligonucleotide of any one of  claims 1 - 15  or the conjugate according to  claim 16  or the pharmaceutical composition of  claim 17  for use in the treatment or prevention of a disease is selected from the group consisting of macular degeneration (such as wetAMD, dryAMD, geographic atrophy, intermediate dAMD, diabetic retinopathy), Parkinson's disease, Alzhiemer's disease, Duchenne muscular dystrophy, arthritis, such as osteoarthritis, and familial ischemic cerebral small-vessel disease.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15635629', '15971951', '14897223', '15971970', '15836144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8056163948313083
- 35 USC 102 Novelty (BERT): 0.5927832920662142
- Combined Prediction Score: 0.784333084554799
- Mean Citation Score: 424.386488
- Max Citation Score: 602.95087
- Similarity Product: 393.7465389000869

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test